Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of out
- PDF / 635,442 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 16 Downloads / 148 Views
ORIGINAL ARTICLE
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group) Florian Zettl 1 & Marita Ziepert 2 & Bettina Altmann 2 & Samira Zeynalova 2 & Gerhard Held 3 & Viola Pöschel 3 & Karin Hohloch 4,5 & Gerald G. Wulf 4 & Bertram Glass 6 & Norbert Schmitz 7 & Markus Loeffler 2 & Lorenz Trümper 4 Received: 14 July 2020 / Accepted: 11 November 2020 # The Author(s) 2020
Abstract In elderly patients (pts) with aggressive B cell lymphoma (aNHL), curative treatment often cannot be administered because of comorbidities and tolerability. We analyzed the influence of age in pts > 60 years receiving the R-CHOP-14 regimen within different prospective DSHNHL trials. Of the RICOVER-60 trial and CHOP-R-ESC trials, 1171 aNHL pts were included in this retrospective analysis of age-dependent event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). All patients received prophylactic G-CSF, and anti-infective prophylaxis with amphotericin B mouth wash and oral fluorchinolone was optional. In the CHOP-R-ESC trials, prophylaxis was augmented to include mandatory continuous orally administered aciclovir and a pneumocystis prophylaxis with cotrimoxazole as well as oral fluorchinolones during neutropenia. The patient population was separated into 4 age groups (61–65 years, 66–70 years, 71–75 years, and 76–80 years). The results from the RICOVER-60 trial were subsequently confirmed in the following CHOP-R-ESC trials by a multivariate analysis adjusted for IPI factors and gender. Significant differences (p < 0.001) in EFS, PFS, and OS were seen between age groups (RICOVER-60). Florian Zettl and Marita Ziepert contributed equally to this work. Supported by Deutsche Krebshilfe, dedicated to Michael Pfreundschuh (deceased) former chairman and founder of the German High-Grade NonHodgkin’s Lymphoma Study Group, outstanding scientist, and clinician Presented at the Annual Meeting of the American Society of Clinical Oncology, 2016 (Reference: Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL. Florian Zettl, Marita Ziepert, Bettina Altmann, Samira Zeynalova, Markus Loeffler, Norbert Schmitz, Michael Pfreundschuh, Karin Hohloch, and Lorenz Trümper; Journal of Clinical Oncology 2016 34:15_suppl, 7539-7539) * Florian Zettl [email protected] 1
Department of Hematology, Oncology and Palliative Care, Klinikum Traunstein, Traunstein, Germany
2
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
3
Department of Internal Medicine, University Hospital Saarland, Homburg, Germany
4
Department of Hematology and Medical
Data Loading...
